Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Rehabilitation Following Nasal Skin Cancer
NCT ID: NCT07257094
Last Updated: 2026-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
346 participants
OBSERVATIONAL
2026-01-10
2027-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesize that the validated French version will provide a reliable and standardized tool to assess patient satisfaction and health-related quality of life in this context.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure
NCT00530049
Feasibility Study of a Transition Pathway at Discharge From Full Hospitalization in Oncology
NCT07256444
Prospective Observational Study to Investigate the Added Value of the Health Related Quality of Life and Patient Reported Symptoms in the Identification of the Recommended Phase II Dose in Phase I Trials of Molecularly Targeted Therapies.
NCT02857699
Cancer and Disorders of Cognitive Functions and Quality of Life: "Cognitive Rehabilitation in Patients Suffering From Cancer and Treated With Chemotherapy"
NCT01788618
Oral Therapies in Oncology: Cognitive Function and Compliance
NCT01597284
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
FACE-Q is an internationally recognized, patient-reported outcome instrument designed to assess satisfaction with appearance, health-related quality of life, and treatment-related adverse effects. However, FACE-Q was developed and validated in English and requires cultural and linguistic adaptation for reliable use in French-speaking populations.
This non-interventional, multicenter study aims to translate and validate the relevant FACE-Q Aesthetics scales in French for patients who have undergone nasal reconstruction or prosthetic rehabilitation after skin cancer. The selected domains address facial and nasal appearance, psychosocial well-being, social function, satisfaction with outcomes, and procedure-related adverse effects.
The expected outcome is to provide a standardized and validated French-language tool that reliably evaluates these patients' satisfaction and quality of life. Such a tool may be applied in clinical practice and future comparative research to improve patient care.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Operated patients
Patients with skin cancer in the nasal region who have undergone surgical reconstruction using a flap or rehabilitation using a prosthesis.
operated patients
Response to the Nasal Reconstruction FACE-Q questionnaire, which includes the following scales :
* Appearence : Face overall, nose, nostrils, skin
* Health related quality of life (HRQOL) : Early life impact, psychological, social, outcome
* Adverse effects : on the nose, on the forehead, eyebrows and scalp
* Nasal Obstruction Symptom Evaluation (NOSE)
* Short-Form-36 (SF 36)
Control
Patients with no history of surgery or facial trauma
Control
Response to the Nasal Reconstruction FACE-Q questionnaire, which includes the following scales :
* Appearence : Face overall, nose, nostrils, skin impact psychological, impact social,
* SF36
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
operated patients
Response to the Nasal Reconstruction FACE-Q questionnaire, which includes the following scales :
* Appearence : Face overall, nose, nostrils, skin
* Health related quality of life (HRQOL) : Early life impact, psychological, social, outcome
* Adverse effects : on the nose, on the forehead, eyebrows and scalp
* Nasal Obstruction Symptom Evaluation (NOSE)
* Short-Form-36 (SF 36)
Control
Response to the Nasal Reconstruction FACE-Q questionnaire, which includes the following scales :
* Appearence : Face overall, nose, nostrils, skin impact psychological, impact social,
* SF36
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient who has undergone excision of a cutaneous, mucocutaneous, or vestibular nasal cancer with surgical reconstruction using a flap or prosthetic rehabilitation, performed more than 4 months ago, with stable results, and less than 3 years ago
* Patient informed of the study and not opposed to participation
* Age ≥ 65 years
* Subject informed and not opposed to participating in the study
* Subject who has never undergone facial trauma or surgery, and without major comorbidity, defined as follows:
* No heart failure (moderate or severe heart failure, history of heart attack within the last 6 months);
* No severe chronic respiratory disease (no stage III-IV COPD, no prolonged oxygen therapy);
* No uncontrolled diabetes or associated severe complications;
* No active immunosuppressive diseases or high-dose immunosuppressive treatment;
* No unstable or severe facial dermatological conditions;
* No comorbidities seriously affecting quality of life or respiratory function (at the investigator's discretion).
Exclusion Criteria
* Patient under legal protection (e.g., guardianship, legal safeguard) or with limited legal capacity
* Patient unlikely to cooperate with the study and/or poor anticipated compliance as judged by the investigator (including psychiatric disorders other than depressive disorder or cognitive impairment)
* Pregnant or breastfeeding woman
CONTROL
* Non-English speaking subject
* Subject under guardianship or legal protection, legally incompetent or with limited legal capacity
* Subject unlikely to cooperate in the study and/or anticipated low cooperation by the investigator (particularly those with psychiatric disorders other than depression or cognitive disorders)
* Pregnant or breastfeeding women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hôpital NOVO
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Khaled AL TABAA, Doctor
Role: STUDY_DIRECTOR
Hôpital NOVO
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Caen
Caen, , France
Centre Antoine Lacassagne
Nice, , France
Institut Curie
Paris, , France
Hôpital Lariboisière (AP-HP)
Paris, , France
Hôpital Bichat (APHP)
Paris, , France
Hopital Novo
Pontoise, , France
HNIA Toulon
Toulon, , France
CHU Toulouse
Toulouse, , France
Institut Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHRD 1424
Identifier Type: OTHER
Identifier Source: secondary_id
2025-A02195-44
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.